Program Chair
Millie Das, MD
Clinical Associate Professor
Stanford University School of Medicine
Chief of Oncology, VA Palo Alto Healthcare System
Palo Alto, California
PROGRAM OVERVIEW
This activity aims to enhance clinicians’ expertise in managing lung cancer in veterans by improving their ability to implement effective lung cancer screening strategies, apply precision oncology through biomarker-driven approaches, select appropriate targeted therapies across various stages of NSCLC treatment, and optimize patient outcomes by proactively addressing immune-related adverse effects associated with immune checkpoint inhibitor therapy.
TARGET AUDIENCE
This activity is designed to meet the educational needs of VA clinicians involved in the evaluation and management of veterans with lung cancer, including medical and radiation oncologists, pulmonologists, radiologists, thoracic surgeons, and advanced practice providers (eg, oncology nurses, pharmacists, nurse practitioners).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Readily identify veteran patients eligible for LCS and potential barriers to LCS completion, and engage in SDM to improve the timely and accurate diagnosis of NSCLC
- Identify opportunities for biomarker testing to inform precision oncology approaches and consider patient factors when developing treatment plans for veterans with NSCLC
- Explain available and emerging targeted treatment options across NSCLC lines of therapy
- Develop proactive strategies to mitigate, identify, and manage emerging irAEs in veteran patients with NSCLC receiving ICI treatment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Millie Das, MD | Advisory Boards: Janssen, AstraZeneca, Bristol Myers Squibb, EMD Serono, Natera, Merus, OncoHost, Jazz Pharmaceuticals, Summit Therapeutics, Novartis, Genentech, Boehringer Ingelheim, RayzeBio. Consulting: Janssen, Gilead Sciences, Daiichi Sankyo, Bristol Myers Squibb, Jazz Pharmaceuticals. Research Support: Amgen, CellSight Technologies, Genentech, Merck, Varian Medical Systems. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, M.S., Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
- Caitlin Rothermel, MPH, Medical Director for Med Learning Group, has nothing to disclose.
- A nurse reviewer has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
